Odyssey Therapeutics reports positive OD-001 Phase 2a results
Odyssey Therapeutics said OD-001 met Phase 2a success criteria and reported $433 million in cash, expected to fund operations into H2 2028.
Key Highlights:Original SEC Filing: Odyssey Therapeutics, Inc. [ ODTX ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider v…